Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study.
By Robin L. Carhart-Harris, M. Bolstridge, J. Rucker, Camilla M. Day, D. Erritzoe, M. Kaelen, M. Bloomfield, J. Rickard, Ben Forbes, A. Feilding and 4 more. Lancet psychiatry, 2016
1,242 citations recorded by the source corpus.
BACKGROUND Psilocybin is a serotonin receptor agonist that occurs naturally in some mushroom species. Recent studies have assessed the therapeutic potential of psilocybin for various conditions, including end-of-life anxiety, obsessive-compulsive disorder, and smoking and alcohol dependence, with promising preliminary results. Here, we aimed to investigate the feasibility, safety, and efficacy of psilocybin in patients with unipolar treatment-resistant depression. METHODS In this open-label feasibility trial, 12 patients (six men, six women) with moderate-to-severe, unipolar, treatment-resistant major depression received two oral doses of psilocybin (10 mg and 25 mg, 7 days apart) in a supportive setting. There was no control group. Psychological support was provided before, during, and after each session. The primary outcome measure for feasibility was patient-reported intensity of psilocybin's effects. Patients were monitored for adverse reactions during the dosing sessions and subsequent clinic and remote follow-up. Depressive symptoms were assessed with standard assessments from 1 week to 3 months after treatment, with the 16-item Quick Inventory of Depressive Symptoms (QIDS) serving as the primary efficacy outcome. This trial is registered with ISRCTN, number ISRCTN14426797. FINDINGS Psilocybin's acute psychedelic effects typically became detectable 30-60 min after dosing, peaked 2-3 h after dosing, and subsided to negligible levels at least 6 h after dosing. Mean self-rated intensity (on a 0-1 scale) was 0·51 (SD 0·36) for the low-dose session and 0·75 (SD 0·27) for the high-dose session. Psilocybin was well tolerated by all of the patients, and no serious or unexpected adverse events occurred. The adverse reactions we noted were transient anxiety during drug onset (all patients), transient confusion or thought disorder (nine patients), mild and transient nausea (four patients), and transient headache (four patients). Relative to baseline, depressive symptoms were markedly reduced 1 week (mean QIDS difference -11·8, 95% CI -9·15 to -14·35, p=0·002, Hedges' g=3·1) and 3 months (-9·2, 95% CI -5·69 to -12·71, p=0·003, Hedges' g=2) after high-dose treatment. Marked and sustained improvements in anxiety and anhedonia were also noted. INTERPRETATION This study provides preliminary support for the safety and efficacy of psilocybin for treatment-resistant depression and motivates further trials, with more rigorous designs, to better examine the therapeutic potential of this approach. FUNDING Medical Research Council.
Subfields: Clinical Psychology, Cognitive Neuroscience, Toxicology
View Paper: https://www.semanticscholar.org/paper/006d3597cc21e0200eb70aab18a11379644d48b8
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Clinical Psychology
- Robin L. Carhart-Harris
- David J. Nutt
- Karl J. Friston
- Roland R. Griffiths
- Matthew W. Johnson
- R. Watts
- Camilla M. Day
- Guy M. Goodwin
In Cognitive Neuroscience
- Robin L. Carhart-Harris
- David J. Nutt
- A. Feilding
- Karl J. Friston
- Rafal Bogacz
- W. D. Penny
- Klaas E. Stephan
- Jean Daunizeau
In Toxicology
- Robin L. Carhart-Harris
- Roland R. Griffiths
- Matthew W. Johnson
- David J. Nutt
- Mary P Cosimano
- David E. Nichols
Citations in the corpus
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial (2016, background): “In two recently published open-label trials, one using a single dose of ayahuasca (Osorio et al., 2015) and the other using two doses of oral psilocybin (Carhart-Harris et al., 2016), acute and enduring anti-depressant effects were reported.”
- Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. (2022, neutral): “of participants (%) 16 (20) 4 (5) 8 (10)”
- Psilocybin-assisted therapy of major depressive disorder using Acceptance and Commitment Therapy as a therapeutic frame (2020, background): “” Some large-scale clinical trials of psilocybin treatment for major depressive disorder currently being implemented are employing nonspecific models of “psychological support” (Carhart-Harris et al., 2016).”
- The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future (2017, background): “…clinical development of psychedelics, RLC-H sees it as a potentially exploitable component—especially as it has been shown to be predictive of long-term clinical outcomes (eg, in Johnson et al, 2014; Bogenschutz et al, 2015; Griffiths et al, 2016; Ross et al, 2016; Carhart-Harris et al, 2016a,b).”
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial (2016, background): “Also relevant, a recent open-label pilot study in 12 patients with treatment-resistant depression showed marked reductions in depressive symptoms 1 week and 3 months after administration of 10 and 25 mg of psilocybin in two sessions separated by 7 days (Carhart-Harris et al., 2016).”
- Psilocybin with psychological support for treatment-resistant depression: six-month follow-up (2017, methodology): “Recent studies (Griffiths et al. 2016; Ross et al. 2016; Carhart-Harris et al. 2016), including the present one, help demonstrate the feasibility of treating patients with major depressive disorder with psilocybin plus psychological support.”
- Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial (2018, background): “substances affect the brain, and also probing their potential in treating different psychiatric conditions, including mood disorders (Grob et al., 2011; Osório et al., 2015; Carhart-Harris et al., 2016; Griffiths et al., 2016; Ross et al., 2016; Sanches et al., 2016).”
- REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics (2019, background): “It has previously been suggested and demonstrated (Gouzoulis et al., 1994; Carhart-Harris et al., 2016b) that the acute psychedelic experience is a much better model of the early (and perhaps acute) symptoms of an incipient psychosis than symptoms associated with chronic schizophrenia, presumably…”
- Serotonin and brain function: a tale of two receptors (2017, methodology): “SSRIs are established evidence-based treatments for anxiety and major depression (Baldwin et al., 2016; Hieronymus et al., 2016), whereas psychedelics are experimental medicines in an early phase of development (Carhart-Harris and Goodwin, 2017; Carhart-Harris et al., 2016).”